Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo aims to rebuild bone in spinal cord injury patients

NCT ID NCT04232657

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 1 time

Summary

This study tests whether a two-step drug treatment can improve bone density in people with long-term spinal cord injury who have bone loss. Participants receive either romosozumab (a bone-building drug) or a placebo for 12 months, followed by denosumab (a bone-strengthening drug) for another 12 months. The goal is to see if this approach can safely increase bone mass and reduce fracture risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

36 people

The number who actually took part.

Started

Mar 2021

Finished

Aug 2026

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Motor-complete or incomplete spinal cord injury (SCI) \[all levels of lesion\] classified using International Standards for Neurological Classification for Spinal Cord Injury (ISNCSCI) impairment scale\] as ISNCSCI score A-C * Duration of injury \>3 years * Males (18-65 years old) and females (premenopausal, between the ages of 18 and 55 years old). * Areal bone mineral density (aBMD) at the distal femur \<1.0 g/cm2 (determined at screening) Exclusion Criteria: * Long-bone fracture of the leg within the past year * History of prior bone disease (Paget's hyperparathyroidism, etc.) * Active and/or history of coronary heart disease or stroke within the past year * Postmenopausal women * Men with known hypogonadism prior to spinal cord injury (SCI) * Anabolic therapy longer than six months duration after spinal cord injury (SCI) * Glucocorticoid administration longer than three months duration within the last year, and/or prescribed moderate or high dose corticosteroids (\>40 mg/d prednisone or an equivalent dose of other corticosteroid medication) for longer than one week, not including drug administered to preserve neurological function at the time of acute spinal cord injury (SCI) * Endocrinopathies (hyperthyroidism, Cushing's disease or syndrome, etc.) * Severe underlying chronic disease (e.g., COPD, end-stage heart disease, chronic renal failure) * Heterotopic ossification (HO) of the knee region (the distal femoral epiphysis is the primary endpoint); HO to any other boney region will not prevent study participation as long as contraindicated medications have not been prescribed) * Chronic alcohol abuse * Hypocalcemia * Pregnancy * Prescribed a bisphosphonate for HO, or prescribed any other agent to treat osteoporosis other than calcium and vitamin D * Electrical stimulation of the lower extremities * Current diagnosis of cancer or history of cancer * Osteosarcoma * Life expectancy less than 5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoporosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • James J. Peters VA Medical Center, Bronx, NY

    The Bronx, New York, 10468-3904, United States

  • Kessler Institute for Rehabilitation

    West Orange, New Jersey, 07052, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.